FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-25

Price

$14.43

+0.14%

Score7.2Priority

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.5xvs 20d avg

Analysis

The price action in Amicus Therapeutics (FOLD) is entirely dictated by its pending $4.8 billion all-cash acquisition by BioMarin at $14.50 per share. Technical signals like QUIET_STORM and STEADY_CLIMB, combined with exceptionally low 2.0% volatility, perfectly capture a stock trading as a tightening merger arbitrage proxy. Under the current RISK_OFF geopolitical regime, this definitive M&A catalyst provides a safe haven for institutional capital, explaining the stock's +6.2% relative outperformance against a volatile broader market. Conviction is high as the stock acts as a defensive cash-equivalent, methodically grinding to yield the final $0.07 spread ahead of its Q2 2026 close.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUEINSIDE OUT

Key Takeaways

Actionable Thesis: FOLD is a pure merger arbitrage play, offering a definitive ceiling at the $14.50 BioMarin buyout price and insulating capital from market volatility.
Key Risk: The asymmetrical downside of an unexpected deal collapse, regulatory intervention, or financing failure, which would aggressively re-price the stock to its standalone fundamental value.
What to Watch: Monitor the timeline for the final closing of the BioMarin transaction expected in Q2 2026, alongside any late-stage antitrust or regulatory filings.

← Back to 2026-03-25 View Full FOLD History →Yahoo Finance &nearr;